• 1
    Leite LP, Johnston BT, Barrett J, Castell JA, Castell DO. Ineffective esophageal motility (IEM): the primary finding in patients with nonspecific esophageal motility disorder. Dig Dis Sci 1997; 42: 185965.
  • 2
    Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. Gut 2001; 49: 14551.
  • 3
    Kahrilas PJ, Dodds WJ, Hogan WJ. Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology 1988; 94: 7380.
  • 4
    Roman S, Lin Z, Kwiatek MA, Pandolfino JE, Kahrilas PJ. Weak peristalsis in esophageal pressure topography: classification and association with Dysphagia. Am J Gastroenterol 2011; 106: 34956.
  • 5
    Fox M, Bredenoord AJ. High resolution manometry: moving from research into clinical practice. Gut 2008; 57: 40523.
  • 6
    Richter JE, Wu WC, Johns DN et al. Esophageal manometry in 95 healthy adult volunteers. Variability of pressures with age and frequency of “abnormal” contractions. Dig Dis Sci 1987; 32: 58392.
  • 7
    Ghosh SK, Pandolfino JE, Zhang Q, Jarosz A, Shah N, Kahrilas PJ. Quantifying esophageal peristalsis with high-resolution manometry: a study of 75 asymptomatic volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G98897.
  • 8
    Vega KJ, Langford-Legg T, Jamal MM. Ethnic variation in lower oesophageal sphincter pressure and length. Aliment Pharmacol Ther 2008; 28: 6559.
  • 9
    Tutuian R, Castell DO. Combined multichannel intraluminal impedance and manometry clarifies esophageal function abnormalities: study in 350 patients. Am J Gastroenterol 2004; 99: 10119.
    Direct Link:
  • 10
    Conchillo JM, Nguyen NQ, Samsom M, Holloway RH, Smout AJ. Multichannel intraluminal impedance monitoring in the evaluation of patients with non-obstructive Dysphagia. Am J Gastroenterol 2005; 100: 262432.
    Direct Link:
  • 11
    Dekel R, Pearson T, Wendel C, De Garmo P, Fennerty MB, Fass R. Assessment of oesophageal motor function in patients with dysphagia or chest pain – the Clinical Outcomes Research Initiative experience. Aliment Pharmacol Ther 2003; 18: 10839.
  • 12
    Diener U, Patti MG, Molena D, Fisichella PM, Way LW. Esophageal dysmotility and gastroesophageal reflux disease. J Gastrointest Surg 2001; 5: 2605.
  • 13
    Lee J, Anggiansah A, Anggiansah R, Young A, Wong T, Fox M. Effects of age on the gastroesophageal junction, esophageal motility, and reflux disease. Clin Gastroenterol Hepatol 2007; 5: 13928.
  • 14
    Fouad YM, Katz PO, Hatlebakk JG, Castell DO. Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. Am J Gastroenterol 1999; 94: 14647.
    Direct Link:
  • 15
    Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 2006; 23: 691712.
  • 16
    Cheng L, Cao W, Fiocchi C, Behar J, Biancani P, Harnett KM. Platelet-activating factor and prostaglandin E2 impair esophageal ACh release in experimental esophagitis. Am J Physiol Gastrointest Liver Physiol 2005; 289: G41828.
  • 17
    Rieder F, Cheng L, Harnett KM et al. Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities. Gastroenterology 2007; 132: 15465.
  • 18
    Fox M, Forgacs I. Gastro-oesophageal reflux disease. BMJ 2006; 332: 8893.
  • 19
    Timmer R, Breumelhof R, Nadorp JH, Smout AJ. Oesophageal motility and gastro-oesophageal reflux before and after healing of reflux oesophagitis. A study using 24 hour ambulatory pH and pressure monitoring. Gut 1994; 35: 151922.
  • 20
    Fibbe C, Layer P, Keller J, Strate U, Emmermann A, Zornig C. Esophageal motility in reflux disease before and after fundoplication: a prospective, randomized, clinical, and manometric study. Gastroenterology 2001; 121: 514.
  • 21
    Kim HS, Park H, Lim JH et al. Morphometric evaluation of oesophageal wall in patients with nutcracker oesophagus and ineffective oesophageal motility. Neurogastroenterol Motil 2008; 20: 86976.
  • 22
    Sweis R, Anggiansah A, Wong T, Kaufman E, Obrecht S, Fox M. Normative values and inter-observer agreement for liquid and solid bolus swallows in upright and supine positions as assessed by esophageal high-resolution manometry. Neurogastroenterol Motil 2011; 23: 509e198.
  • 23
    Nguyen NQ, Tippett M, Smout AJ, Holloway RH. Relationship between pressure wave amplitude and esophageal bolus clearance assessed by combined manometry and multichannel intraluminal impedance measurement. Am J Gastroenterol 2006; 101: 247684.
    Direct Link:
  • 24
    Bulsiewicz WJ, Kahrilas PJ, Kwiatek MA, Ghosh SK, Meek A, Pandolfino JE. Esophageal pressure topography criteria indicative of incomplete bolus clearance: a study using high-resolution impedance manometry. Am J Gastroenterol 2009; 104: 27218.
  • 25
    Fox M, Hebbard G, Janiak P et al. High-resolution manometry predicts the success of oesophageal bolus transport and identifies clinically important abnormalities not detected by conventional manometry. Neurogastroenterol Motil 2004; 16: 53342.
  • 26
    Sweis R, Anggiansah A, Wong T, Fox M. Inclusion of solid swallows and a test meal increase the clinical utility of High Resolution Manometry in patients with dysphagia. Gastroenterology 2010; 138: S 600 (T1889).
  • 27
    Daum C, Sweis R, Kaufman E et al. Failure to respond to physiologic challenge characterizes esophageal motility in erosive gastro-esophageal reflux disease. Neurogastroenterol Motil 2011; 23: 517e200.
  • 28
    Pouderoux P, Shi G, Tatum RP, Kahrilas PJ. Esophageal solid bolus transit: studies using concurrent videofluoroscopy and manometry. Am J Gastroenterol 1999; 94: 145763.
    Direct Link:
  • 29
    Simren M, Silny J, Holloway R, Tack J, Janssens J, Sifrim D. Relevance of ineffective oesophageal motility during oesophageal acid clearance. Gut 2003; 52: 78490.
  • 30
    Holdaway A, Davis M. Palliation in cancer of the oesophagus – what passes down an oesophageal stent? J Hum Nutr Dietet 2003; 16: 36570.
  • 31
    Mohammed SH, Hegedus V. Dislodgement of impacted oesophageal foreign bodies with carbonated beverages. Clin Radiol 1986; 37: 58992.
  • 32
    Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 126582.
  • 33
    Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 96571.
  • 34
    Fox M, Barr C, Nolan S, Lomer M, Anggiansah A, Wong T. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms. Clin Gastroenterol Hepatol 2007; 5: 43944.
  • 35
    Moazzez R, Bartlett D, Anggiansah A. The effect of chewing sugar-free gum on gastro-esophageal reflux. J Dent Res 2005; 84: 10625.
  • 36
    Hendel L, Hage E, Hendel J, Stentoft P. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992; 6: 56577.
  • 37
    Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. Eur J Pediatr 1987; 146: 1568.
  • 38
    Janiak P, Thumshirn M, Menne D et al. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis – a randomized controlled, cross-over trial. Aliment Pharmacol Ther 2007; 26: 125965.
  • 39
    Agrawal A, Hila A, Tutuian R, Mainie I, Castell DO. Bethanechol improves smooth muscle function in patients with severe ineffective esophageal motility. J Clin Gastroenterol 2007; 41: 36670.
  • 40
    Blonski W, Vela MF, Freeman J, Sharma N, Castell DO. The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. J Clin Gastroenterol 2009; 43: 25360.
  • 41
    Takahashi T, Kurosawa S, Wiley JW, Owyang C. Mechanism for the gastrokinetic action of domperidone. In vitro studies in guinea pigs. Gastroenterology 1991; 101: 70310.
  • 42
    Tonini M, Candura SM, Messori E, Rizzi CA. Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Pharmacol Res 1995; 31: 25760.
  • 43
    Maddern GJ, Kiroff GK, Leppard PI, Jamieson GG. Domperidone, metoclopramide, and placebo. All give symptomatic improvement in gastroesophageal reflux. J Clin Gastroenterol 1986; 8: 13540.
  • 44
    Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999; 60: 4227.
  • 45
    Maddern GJ, Horowitz M, Jamieson GG. The effect of domperidone on oesophageal emptying in diabetic autonomic neuropathy. Br J Clin Pharmacol 1985; 19: 4414.
  • 46
    Drane WE, Karvelis K, Johnson DA, Curran JJ, Silverman ED. Scintigraphic detection of metoclopramide esophageal stimulation in progressive systemic sclerosis. J Nucl Med 1987; 28: 8105.
  • 47
    Quigley EM. Gastric and small intestinal motility in health and disease. Gastroenterol Clin North Am 1996; 25: 11345.
  • 48
    Chrysos E, Tzovaras G, Epanomeritakis E et al. Erythromycin enhances oesophageal motility in patients with gastro-oesophageal reflux. ANZ J Surg 2001; 71: 98102.
  • 49
    Chang CT, Shiau YC, Lin CC, Li TC, Lee CC, Kao CH. Improvement of esophageal and gastric motility after 2-week treatment of oral erythromycin in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 2003; 17: 1414.
  • 50
    Van Herwaarden MA, Samsom M, Van Nispen CH, Verlinden M, Smout AJ. The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients. Aliment Pharmacol Ther 2000; 14: 45362.
  • 51
    Gershon MD. Review article: serotonin receptors and transporters – roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004; 20(Suppl. 7): 314.
  • 52
    Sanger GJ. Translating 5-HT receptor pharmacology. Neurogastroenterol Motil 2009; 21: 12358.
  • 53
    Smout AJ, Bogaard JW, Grade AC, ten Thije OJ, Akkermans LM, Wittebol P. Effects of cisapride, a new gastrointestinal prokinetic substance, on interdigestive and postprandial motor activity of the distal oesophagus in man. Gut 1985; 26: 24651.
  • 54
    Ruth M, Finizia C, Cange L, Lundell L. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003; 15: 111521.
  • 55
    Koshino K, Adachi K, Furuta K et al. Effects of mosapride on esophageal functions and gastroesophageal reflux. J Gastroenterol Hepatol 2010; 25: 106671.
  • 56
    Staiano A, Clouse RE. The effects of cisapride on the topography of oesophageal peristalsis. Aliment Pharmacol Ther 1996; 10: 87582.
  • 57
    Fox M, Menne D, Stutz B, Fried M, Schwizer W. The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. Aliment Pharmacol Ther 2006; 24: 101727.
  • 58
    Pandolfino JE, Kwiatek MA, Ho K, Scherer JR, Kahrilas PJ. Unique features of esophagogastric junction pressure topography in hiatus hernia patients with dysphagia. Surgery 2010; 147: 5764.
  • 59
    Herbella FA, Tedesco P, Nipomnick I, Fisichella PM, Patti MG. Effect of partial and total laparoscopic fundoplication on esophageal body motility. Surg Endosc 2007; 21: 2858.
  • 60
    Munitiz V, Ortiz A, Martinez de Haro LF, Molina J, Parrilla P. Ineffective oesophageal motility does not affect the clinical outcome of open Nissen fundoplication. Br J Surg 2004; 91: 10104.